- +1-315-215-1633
- sales@thebrainyinsights.com
The global genome editing market was valued at USD 5.89 billion in 2022, increasing at a CAGR of 16.85% from 2022 to 2030 and anticipated to reach USD 20.47 billion by 2030. The global genome editing market was valued at USD 5.89 billion in 2022, increasing at a CAGR of 16.85% from 2022 to 2030 and anticipated to reach USD 20.47 billion by 2030. Asia-Pacific is expected to grow the fastest during the forecast period. Furthermore, the increasing government funding, rise in the production of genetically modified crops, and growth in the number of genomics projects are expected to drive market growth.
CRISPR-Cas9 is a unique technology that permits geneticists & medical researchers to edit parts of the genome by altering, removing, or adding sections of the DNA sequence. CRISPRs are technical stretches of DNA. Multiple genome-editing tools exist, such as transcription activator-like effector nucleases (TALENs), zinc-finger nucleases (ZFNs), mega nucleases, and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) methods. The CRISPR-Cas9 (CRISPR-associated protein 9) system is the most successful.
Genome editing (also known as gene editing) is a group of technologies that give scientists the ability to change an organism's DNA. The development of new approaches based on the CRISPR-Cas9 system has made this process much more affordable, efficient, and flexible relative to previous strategies. CRISPR could be utilized to alter disorder-causing genes in embryos carried to term, removing the faulty script from the genetic code of that individual's future descendants. Genome editing could even eliminate or potentially decrease the incidence of many severe genetic disorders, reducing human suffering globally. These technologies permit genetic material to be removed, added, or altered at particular locations in the genome. Genome editing technologies allow scientists to change DNA, leading to changes in physical traits, like eye color & disease risk. Genome editing is of great interest in preventing & treating human diseases. Scientists are still operating to determine whether this strategy is effective and safe for use in people. It is being explored in research & clinical trials for various diseases, including single-gene diseases like cystic fibrosis, hemophilia, and sickle cell illness. It also holds promise for preventing & treating more complex conditions, like heart disease, mental illness, cancer, and human immunodeficiency virus (HIV) infection.
Get an overview of this study by requesting a free sample
For example, in January 2020, New England Biolabs cooperated with ERS Genomics to commercialize and develop CRISPR gene editing tools & reagents.
Drivers:
The increased incidence of genetic disorders: The expanding use of genome engineering in treating chronic illnesses and therapies drives market growth. Early, precise, and quick treatment via transcriptome, genomic, or other multi-omics cells causing chronic and infectious diseases propel the market growth. Further, private & government funding, the rise in the technology development in CRISPR gene editing, and the growing developments in gene therapy are also helping to propel the market growth. Apart from this, the usage of genome editing in treating these diseases has mainly grown in current years due to the ongoing incidence of chronic and infectious diseases such as HIV/AIDS, malaria, hepatitis, TB, and others. This factor is also stimulating market growth.
The increase in demand for synthetic genes: The supportive government guidelines associated with synthetic biology, rising demand for synthesized genes and synthesized cells, and surging investments from the government and major players are the driving factor of the market growth. Further, the substantial development in gene therapy & molecular biology is the development and use of different state-of-the-art gene editing techniques for editing purposes, also propelled the market growth. In addition, the development of genome engineering, the availability of user-friendly gene therapy systems, and gene therapy's ability to promote rapid genome-wide interrogation of gene function are also helping to boost market growth during the forecast period.
Restraints:
A high equipment cost: The ethical problems concerning genetic editing, like safety & high expenses involved in gene therapies, hamper the market growth. Further, the high treatment & maintenance prices for genome alteration therapies and related treatments and a lack of infrastructure in low and medium-income nations are also restraining the market growth. Also, the lack of public awareness in underdeveloped economies and the off-target effects of CRISPR technology hinder the market growth. In addition, the off-target effects include unintended point mutations, insertions, deletions, and translocations. Off-target genome editing refers to nonspecific & unintended genetic modifications that can occur through the usage of engineered nuclease technologies like transcription activator-like effector nucleases (TALEN), zinc finger nucleases (ZFN) meganucleases, and clustered, regularly interspaced, short palindromic repeats (CRISPR)-Cas9. In addition, a significant concern is a high frequency of off-target activity (≥50%) mutations at locations other than the intended on-target site.
Opportunities:
The increased application areas of genomics: Antiviral applications for treating uncured illnesses such as herpes, HIV, and hepatitis B are the driving factor of the market growth. Also, the more substantial applications contain biotechnology, mutation and agriculture, and therapeutics. These technologies present many openings in crop advancement in gene-targeted exchange therapy that is not yet grasped. Furthermore, the growth of the cell & gene therapy area and the CRISPR gene editing scope in the agriculture sector is one of the opportunity factors of the market growth. However, the ever-increasing R&D funding for different research organizations in developing countries is helping to propel market growth. Also, the development of new drugs and the identification & management of human genetic diseases stimulate market growth during the forecast period.
Regional segmentation analysis:
The regions analyzed for the market include Europe, South America, Asia Pacific, North America, the Middle East, and Africa. North America emerged as the largest market for the global genome editing market, with a 46.34% share of the market revenue in 2022. North America dominates the genome editing market due to the improved healthcare infrastructure. Further, the high penetration of animal genetic companies with advanced technologies, the presence of healthcare programs, and an increasing number of laboratories propel the market growth in this region. In addition, the presence of major market players in the US, along with the significant investment in R&D activities, are also helping to drive market growth. The Asia Pacific is expected to grow the fastest during the forecast period due to the increased government funding for biotechnology to improve disease treatment. In addition, the upsurge in disposable income, slow adoption of technology, high demand for animal proteins, and an unorganized regulatory environment across & within nations are also helping to boost market growth during the forecast period.
North America Region Genome Editing Market Share in 2022 - 46.34%
www.thebrainyinsights.com
Check the geographical analysis of this market by requesting a free sample
Application segment analysis
The application segment is divided into animal genetic engineering, cell line engineering, and plant genetic engineering. The animal genetic engineering segment dominated, with a market share of around 41.21% in 2022. This growth is attributed to the increasing advancements in animal health biotechnology services and the increasing demand for animal protein.
Technology segment analysis
The technology segment is divided into TALENs, zinc finger nucleases (ZFNs), and CRISPR/Cas9. In 2022, the CRISPR/Cas9 segment dominated the market with the largest market share of 43.09% and market revenue of 2.53 billion. This growth is attributed to the ever-increasing demand in the food industry for better products with improved quality & nutrient enrichment. CRISPR is a unique association of short, partway palindromic repeated DNA sequences found in the genomes of bacteria & other microorganisms. CRISPR lines are a vital component of the immune system. CRISPR immune system protects bacteria from ongoing viral infection. Its applications considerably impact comprehension of the genetic basis behind different carcinomas.
End-User segment analysis
The end-user segment is divided into contract research organizations (CROs), biotech and pharma companies, and research institutes. In 2022, the biotech and pharma companies segment dominated the market with the largest market share of 42.16% and market revenue of 2.48 billion. This growth is attributed to rising R&D activities and new trends in treating genetic diseases.
Report Description:
| Attribute | Description |
|---|---|
| Market Size | Revenue (USD Billion) |
| Market size value in 2022 | USD 5.89 Billion |
| Market size value in 2030 | USD 20.47 Billion |
| CAGR (2022 to 2030) | 16.85% |
| Historical data | 2019-2020 |
| Base Year | 2021 |
| Forecast | 2022-2030 |
| Segments | Key Segments are application, technology, end-use, application, and regions |
| Regional Segments | The key regions are North America, South America, Europe, Asia Pacific, and Middle East & Africa. |
North America region emerged as the largest market for the genome editing.
The market's growth will be influenced by the increased incidence of genetic disorders.
The high equipment cost could hamper the market growth.
The increased application areas of genomics will provide huge opportunities to the market.
1. Introduction
1.1. Objectives of the Study
1.2. Market Definition
1.3. Research Scope
1.4. Currency
1.5. Key Target Audience
2. Research Methodology and Assumptions
3. Executive Summary
4. Premium Insights
4.1. Porter’s Five Forces Analysis
4.2. Value Chain Analysis
4.3. Top Investment Pockets
4.3.1. Market Attractiveness Analysis By Application
4.3.2. Market Attractiveness Analysis By Technology
4.3.3. Market Attractiveness Analysis By End-User
4.3.4. Market Attractiveness Analysis By Region
4.4. Industry Trends
5. Market Dynamics
5.1. Market Evaluation
5.2. Drivers
5.2.1. The increasing number of research activities for treating chronic diseases utilizing genome editing technology
5.2.2. The technological advancements in the biotechnology sector
5.2.3. The increased incidence of genetic disorders
5.2.4. The increasing investment in genome editing technologies
5.3. Restraints
5.3.1. A high equipment cost
5.4. Opportunities
5.4.1. The increased application areas of genomics
6. Global Genome Editing Market Analysis and Forecast, By Application
6.1. Segment Overview
6.2. Animal Genetic Engineering
6.3. Cell Line Engineering
6.4. Plant Genetic Engineering
7. Global Genome Editing Market Analysis and Forecast, By Technology
7.1. Segment Overview
7.2. TALENs
7.3. Zinc Finger Nucleases (ZFNs)
7.4. CRISPR/Cas9
8. Global Genome Editing Market Analysis and Forecast, By End-User
8.1. Segment Overview
8.2. Contract Research Organizations (CROs)
8.3. Biotech and Pharma Companies
8.4. Research Institutes
9. Global Genome Editing Market Analysis and Forecast, By Regional Analysis
9.1. Segment Overview
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.2.3. Mexico
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.5. South America
9.5.1. Brazil
9.6. Middle East and Africa
9.6.1. UAE
9.6.2. South Africa
10. Global Genome Editing Market-Competitive Landscape
10.1. Overview
10.2. Market Share of Key Players in Global Genome Editing Market
10.2.1. Global Company Market Share
10.2.2. North America Company Market Share
10.2.3. Europe Company Market Share
10.2.4. APAC Company Market Share
10.3. Competitive Situations and Trends
10.3.1. Product Launches and Developments
10.3.2. Partnerships, Collaborations, and Agreements
10.3.3. Mergers & Acquisitions
10.3.4. Expansions
11. Company Profiles
11.1. Merck KGaA
11.1.1. Business Overview
11.1.2. Company Snapshot
11.1.3. Company Market Share Analysis
11.1.4. Company Product Portfolio
11.1.5. Recent Developments
11.1.6. SWOT Analysis
11.2. Thermo Fisher Scientific
11.2.1. Business Overview
11.2.2. Company Snapshot
11.2.3. Company Market Share Analysis
11.2.4. Company Product Portfolio
11.2.5. Recent Developments
11.2.6. SWOT Analysis
11.3. Lonza
11.3.1. Business Overview
11.3.2. Company Snapshot
11.3.3. Company Market Share Analysis
11.3.4. Company Product Portfolio
11.3.5. Recent Developments
11.3.6. SWOT Analysis
11.4. Sangamo Therapeutics
11.4.1. Business Overview
11.4.2. Company Snapshot
11.4.3. Company Market Share Analysis
11.4.4. Company Product Portfolio
11.4.5. Recent Developments
11.4.6. SWOT Analysis
11.5. GenScript
11.5.1. Business Overview
11.5.2. Company Snapshot
11.5.3. Company Market Share Analysis
11.5.4. Company Product Portfolio
11.5.5. Recent Developments
11.5.6. SWOT Analysis
11.6. Editas Medicine
11.6.1. Business Overview
11.6.2. Company Snapshot
11.6.3. Company Market Share Analysis
11.6.4. Company Product Portfolio
11.6.5. Recent Developments
11.6.6. SWOT Analysis
11.7. Tecan Life Sciences
11.7.1. Business Overview
11.7.2. Company Snapshot
11.7.3. Company Market Share Analysis
11.7.4. Company Product Portfolio
11.7.5. Recent Developments
11.7.6. SWOT Analysis
11.8. CRISPR Therapeutics AG
11.8.1. Business Overview
11.8.2. Company Snapshot
11.8.3. Company Market Share Analysis
11.8.4. Company Product Portfolio
11.8.5. Recent Developments
11.8.6. SWOT Analysis
11.9. Cellectis S.A
11.9.1. Business Overview
11.9.2. Company Snapshot
11.9.3. Company Market Share Analysis
11.9.4. Company Product Portfolio
11.9.5. Recent Developments
11.9.6. SWOT Analysis
11.10. Agilent Technologies
11.10.1. Business Overview
11.10.2. Company Snapshot
11.10.3. Company Market Share Analysis
11.10.4. Company Product Portfolio
11.10.5. Recent Developments
11.10.6. SWOT Analysis
11.11. Precision Biosciences
11.11.1. Business Overview
11.11.2. Company Snapshot
11.11.3. Company Market Share Analysis
11.11.4. Company Product Portfolio
11.11.5. Recent Developments
11.11.6. SWOT Analysis
11.12. Creative Biogene
11.12.1. Business Overview
11.12.2. Company Snapshot
11.12.3. Company Market Share Analysis
11.12.4. Company Product Portfolio
11.12.5. Recent Developments
11.12.6. SWOT Analysis
11.13. Bluebird Bio
11.13.1. Business Overview
11.13.2. Company Snapshot
11.13.3. Company Market Share Analysis
11.13.4. Company Product Portfolio
11.13.5. Recent Developments
11.13.6. SWOT Analysis
11.14. PerkinElmer
11.14.1. Business Overview
11.14.2. Company Snapshot
11.14.3. Company Market Share Analysis
11.14.4. Company Product Portfolio
11.14.5. Recent Developments
11.14.6. SWOT Analysis
11.15. Regeneron Pharmaceuticals
11.15.1. Business Overview
11.15.2. Company Snapshot
11.15.3. Company Market Share Analysis
11.15.4. Company Product Portfolio
11.15.5. Recent Developments
11.15.6. SWOT Analysis
11.16. Intellia Therapeutics
11.16.1. Business Overview
11.16.2. Company Snapshot
11.16.3. Company Market Share Analysis
11.16.4. Company Product Portfolio
11.16.5. Recent Developments
11.16.6. SWOT Analysis
11.17. Vigene Biosciences
11.17.1. Business Overview
11.17.2. Company Snapshot
11.17.3. Company Market Share Analysis
11.17.4. Company Product Portfolio
11.17.5. Recent Developments
11.17.6. SWOT Analysis
11.18. Transposagen Biopharmaceuticals
11.18.1. Business Overview
11.18.2. Company Snapshot
11.18.3. Company Market Share Analysis
11.18.4. Company Product Portfolio
11.18.5. Recent Developments
11.18.6. SWOT Analysis
11.19. Synthego
11.19.1. Business Overview
11.19.2. Company Snapshot
11.19.3. Company Market Share Analysis
11.19.4. Company Product Portfolio
11.19.5. Recent Developments
11.19.6. SWOT Analysis
11.20. Beam Therapeutics
11.20.1. Business Overview
11.20.2. Company Snapshot
11.20.3. Company Market Share Analysis
11.20.4. Company Product Portfolio
11.20.5. Recent Developments
11.20.6. SWOT Analysis
11.21. Caribou Biosciences
11.21.1. Business Overview
11.21.2. Company Snapshot
11.21.3. Company Market Share Analysis
11.21.4. Company Product Portfolio
11.21.5. Recent Developments
11.21.6. SWOT Analysis
11.22. Integrated DNA Technologies
11.22.1. Business Overview
11.22.2. Company Snapshot
11.22.3. Company Market Share Analysis
11.22.4. Company Product Portfolio
11.22.5. Recent Developments
11.22.6. SWOT Analysis
11.23. Recombinetics
11.23.1. Business Overview
11.23.2. Company Snapshot
11.23.3. Company Market Share Analysis
11.23.4. Company Product Portfolio
11.23.5. Recent Developments
11.23.6. SWOT Analysis
11.24. OriGene Technologies
11.24.1. Business Overview
11.24.2. Company Snapshot
11.24.3. Company Market Share Analysis
11.24.4. Company Product Portfolio
11.24.5. Recent Developments
11.24.6. SWOT Analysis
11.25. New England Biolabs
11.25.1. Business Overview
11.25.2. Company Snapshot
11.25.3. Company Market Share Analysis
11.25.4. Company Product Portfolio
11.25.5. Recent Developments
11.25.6. SWOT Analysis
List of Table
1. Global Genome Editing Market, By Application, 2019-2030 (USD Billion)
2. Global Animal Genetic Engineering, Genome Editing Market, By Region, 2019-2030 (USD Billion)
3. Global Cell Line Engineering, Genome Editing Market, By Region, 2019-2030 (USD Billion)
4. Global Plant Genetic Engineering, Genome Editing Market, By Region, 2019-2030 (USD Billion)
5. Global Genome Editing Market, By Technology, 2019-2030 (USD Billion)
6. Global TALENs, Genome Editing Market, By Region, 2019-2030 (USD Billion)
7. Global Zinc Finger Nucleases (ZFNs), Genome Editing Market, By Region, 2019-2030 (USD Billion)
8. Global CRISPR/Cas9, Genome Editing Market, By Region, 2019-2030 (USD Billion)
9. Global Genome Editing Market, By End-User, 2019-2030 (USD Billion)
10. Global Contract Research Organizations (CROs), Genome Editing Market, By Region, 2019-2030 (USD Billion)
11. Global Biotech and Pharma Companies, Genome Editing Market, By Region, 2019-2030 (USD Billion)
12. Global Research Institutes, Genome Editing Market, By Region, 2019-2030 (USD Billion)
13. North America Genome Editing Market, By Application, 2019-2030 (USD Billion)
14. North America Genome Editing Market, By Technology, 2019-2030 (USD Billion)
15. North America Genome Editing Market, By End-User, 2019-2030 (USD Billion)
16. U.S. Genome Editing Market, By Application, 2019-2030 (USD Billion)
17. U.S. Genome Editing Market, By Technology, 2019-2030 (USD Billion)
18. U.S. Genome Editing Market, By End-User, 2019-2030 (USD Billion)
19. Canada Genome Editing Market, By Application, 2019-2030 (USD Billion)
20. Canada Genome Editing Market, By Technology, 2019-2030 (USD Billion)
21. Canada Genome Editing Market, By End-User, 2019-2030 (USD Billion)
22. Mexico Genome Editing Market, By Application, 2019-2030 (USD Billion)
23. Mexico Genome Editing Market, By Technology, 2019-2030 (USD Billion)
24. Mexico Genome Editing Market, By End-User, 2019-2030 (USD Billion)
25. Europe Genome Editing Market, By Application, 2019-2030 (USD Billion)
26. Europe Genome Editing Market, By Technology, 2019-2030 (USD Billion)
27. Europe Genome Editing Market, By End-User, 2019-2030 (USD Billion)
28. Germany Genome Editing Market, By Application, 2019-2030 (USD Billion)
29. Germany Genome Editing Market, By Technology, 2019-2030 (USD Billion)
30. Germany Genome Editing Market, By End-User, 2019-2030 (USD Billion)
31. France Genome Editing Market, By Application, 2019-2030 (USD Billion)
32. France Genome Editing Market, By Technology, 2019-2030 (USD Billion)
33. France Genome Editing Market, By End-User, 2019-2030 (USD Billion)
34. U.K. Genome Editing Market, By Application, 2019-2030 (USD Billion)
35. U.K. Genome Editing Market, By Technology, 2019-2030 (USD Billion)
36. U.K. Genome Editing Market, By End-User, 2019-2030 (USD Billion)
37. Italy Genome Editing Market, By Application, 2019-2030 (USD Billion)
38. Italy Genome Editing Market, By Technology, 2019-2030 (USD Billion)
39. Italy Genome Editing Market, By End-User, 2019-2030 (USD Billion)
40. Spain Genome Editing Market, By Application, 2019-2030 (USD Billion)
41. Spain Genome Editing Market, By Technology, 2019-2030 (USD Billion)
42. Spain Genome Editing Market, By End-User, 2019-2030 (USD Billion)
43. Asia Pacific Genome Editing Market, By Application, 2019-2030 (USD Billion)
44. Asia Pacific Genome Editing Market, By Technology, 2019-2030 (USD Billion)
45. Asia Pacific Genome Editing Market, By End-User, 2019-2030 (USD Billion)
46. Japan Genome Editing Market, By Application, 2019-2030 (USD Billion)
47. Japan Genome Editing Market, By Technology, 2019-2030 (USD Billion)
48. Japan Genome Editing Market, By End-User, 2019-2030 (USD Billion)
49. China Genome Editing Market, By Application, 2019-2030 (USD Billion)
50. China Genome Editing Market, By Technology, 2019-2030 (USD Billion)
51. China Genome Editing Market, By End-User, 2019-2030 (USD Billion)
52. India Genome Editing Market, By Application, 2019-2030 (USD Billion)
53. India Genome Editing Market, By Technology, 2019-2030 (USD Billion)
54. India Genome Editing Market, By End-User, 2019-2030 (USD Billion)
55. South America Genome Editing Market, By Application, 2019-2030 (USD Billion)
56. South America Genome Editing Market, By Technology, 2019-2030 (USD Billion)
57. South America Genome Editing Market, By End-User, 2019-2030 (USD Billion)
58. Brazil Genome Editing Market, By Application, 2019-2030 (USD Billion)
59. Brazil Genome Editing Market, By Technology, 2019-2030 (USD Billion)
60. Brazil Genome Editing Market, By End-User, 2019-2030 (USD Billion)
61. Middle East and Africa Genome Editing Market, By Application, 2019-2030 (USD Billion)
62. Middle East and Africa Genome Editing Market, By Technology, 2019-2030 (USD Billion)
63. Middle East and Africa Genome Editing Market, By End-User, 2019-2030 (USD Billion)
64. UAE Genome Editing Market, By Application, 2019-2030 (USD Billion)
65. UAE Genome Editing Market, By Technology, 2019-2030 (USD Billion)
66. UAE Genome Editing Market, By End-User, 2019-2030 (USD Billion)
67. South Africa Genome Editing Market, By Application, 2019-2030 (USD Billion)
68. South Africa Genome Editing Market, By Technology, 2019-2030 (USD Billion)
69. South Africa Genome Editing Market, By End-User, 2019-2030 (USD Billion)
List of Figures
1. Global Genome Editing Market Segmentation
2. Global Genome Editing Market: Research Methodology
3. Market Size Estimation Methodology: Bottom-Up Approach
4. Market Size Estimation Methodology: Top- Approach
5. Data Triangulation
6. Porter’s Five Forces Analysis
7. Value Chain Analysis
8. Global Genome Editing Market Attractiveness Analysis By Application
9. Global Genome Editing Market Attractiveness Analysis By Technology
10. Global Genome Editing Market Attractiveness Analysis By End-User
11. Global Genome Editing Market Attractiveness Analysis By Region
12. Global Genome Editing Market: Dynamics
13. Global Genome Editing Market Share By Application (2022 & 2030)
14. Global Genome Editing Market Share By Technology (2022 & 2030)
15. Global Genome Editing Market Share By End-User (2022 & 2030)
16. Global Genome Editing Market Share By Regions (2022 & 2030)
17. Global Genome Editing Market Share By Company (2021)
This study forecasts revenue at global, regional, and country levels from 2019 to 2030. The Brainy Insights has segmented the global genome editing based on below mentioned segments:
Global Genome Editing Market by Application:
Global Genome Editing Market by Technology:
Global Genome Editing Market by End-User:
Global Genome Editing by Region:
Research has its special purpose to undertake marketing efficiently. In this competitive scenario, businesses need information across all industry verticals; the information about customer wants, market demand, competition, industry trends, distribution channels etc. This information needs to be updated regularly because businesses operate in a dynamic environment. Our organization, The Brainy Insights incorporates scientific and systematic research procedures in order to get proper market insights and industry analysis for overall business success. The analysis consists of studying the market from a miniscule level wherein we implement statistical tools which helps us in examining the data with accuracy and precision.
Our research reports feature both; quantitative and qualitative aspects for any market. Qualitative information for any market research process are fundamental because they reveal the customer needs and wants, usage and consumption for any product/service related to a specific industry. This in turn aids the marketers/investors in knowing certain perceptions of the customers. Qualitative research can enlighten about the different product concepts and designs along with unique service offering that in turn, helps define marketing problems and generate opportunities. On the other hand, quantitative research engages with the data collection process through interviews, e-mail interactions, surveys and pilot studies. Quantitative aspects for the market research are useful to validate the hypotheses generated during qualitative research method, explore empirical patterns in the data with the help of statistical tools, and finally make the market estimations.
The Brainy Insights offers comprehensive research and analysis, based on a wide assortment of factual insights gained through interviews with CXOs and global experts and secondary data from reliable sources. Our analysts and industry specialist assume vital roles in building up statistical tools and analysis models, which are used to analyse the data and arrive at accurate insights with exceedingly informative research discoveries. The data provided by our organization have proven precious to a diverse range of companies, facilitating them to address issues such as determining which products/services are the most appealing, whether or not customers use the product in the manner anticipated, the purchasing intentions of the market and many others.
Our research methodology encompasses an idyllic combination of primary and secondary initiatives. Key phases involved in this process are listed below:
The phase involves the gathering and collecting of market data and its related information with the help of different sources & research procedures.
The data procurement stage involves in data gathering and collecting through various data sources.
This stage involves in extensive research. These data sources includes:
Purchased Database: Purchased databases play a crucial role in estimating the market sizes irrespective of the domain. Our purchased database includes:
Primary Research: The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. Primary research mainly involves in telephonic interviews, E-mail interactions and face-to-face interviews with the raw material providers, manufacturers/producers, distributors, & independent consultants. The interviews that we conduct provides valuable data on market size and industry growth trends prevailing in the market. Our organization also conducts surveys with the various industry experts in order to gain overall insights of the industry/market. For instance, in healthcare industry we conduct surveys with the pharmacists, doctors, surgeons and nurses in order to gain insights and key information of a medical product/device/equipment which the customers are going to usage. Surveys are conducted in the form of questionnaire designed by our own analyst team. Surveys plays an important role in primary research because surveys helps us to identify the key target audiences of the market. Additionally, surveys helps to identify the key target audience engaged with the market. Our survey team conducts the survey by targeting the key audience, thus gaining insights from them. Based on the perspectives of the customers, this information is utilized to formulate market strategies. Moreover, market surveys helps us to understand the current competitive situation of the industry. To be precise, our survey process typically involve with the 360 analysis of the market. This analytical process begins by identifying the prospective customers for a product or service related to the market/industry to obtain data on how a product/service could fit into customers’ lives.
Secondary Research: The secondary data sources includes information published by the on-profit organizations such as World bank, WHO, company fillings, investor presentations, annual reports, national government documents, statistical databases, blogs, articles, white papers and others. From the annual report, we analyse a company’s revenue to understand the key segment and market share of that organization in a particular region. We analyse the company websites and adopt the product mapping technique which is important for deriving the segment revenue. In the product mapping method, we select and categorize the products offered by the companies catering to domain specific market, deduce the product revenue for each of the companies so as to get overall estimation of the market size. We also source data and analyses trends based on information received from supply side and demand side intermediaries in the value chain. The supply side denotes the data gathered from supplier, distributor, wholesaler and the demand side illustrates the data gathered from the end customers for respective market domain.
The supply side for a domain specific market is analysed by:
The demand side for the market is estimated through:
In-house Library: Apart from these third-party sources, we have our in-house library of qualitative and quantitative information. Our in-house database includes market data for various industry and domains. These data are updated on regular basis as per the changing market scenario. Our library includes, historic databases, internal audit reports and archives.
Sometimes there are instances where there is no metadata or raw data available for any domain specific market. For those cases, we use our expertise to forecast and estimate the market size in order to generate comprehensive data sets. Our analyst team adopt a robust research technique in order to produce the estimates:
Data Synthesis: This stage involves the analysis & mapping of all the information obtained from the previous step. It also involves in scrutinizing the data for any discrepancy observed while data gathering related to the market. The data is collected with consideration to the heterogeneity of sources. Robust scientific techniques are in place for synthesizing disparate data sets and provide the essential contextual information that can orient market strategies. The Brainy Insights has extensive experience in data synthesis where the data passes through various stages:
Market Deduction & Formulation: The final stage comprises of assigning data points at appropriate market spaces so as to deduce feasible conclusions. Analyst perspective & subject matter expert based holistic form of market sizing coupled with industry analysis also plays a crucial role in this stage.
This stage involves in finalization of the market size and numbers that we have collected from data integration step. With data interpolation, it is made sure that there is no gap in the market data. Successful trend analysis is done by our analysts using extrapolation techniques, which provide the best possible forecasts for the market.
Data Validation & Market Feedback: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helps us finalize data-points to be used for final calculations.
The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. The data validation interview and discussion panels are typically composed of the most experienced industry members. The participants include, however, are not limited to:
Moreover, we always validate our data and findings through primary respondents from all the major regions we are working on.
Free Customization
Fortune 500 Clients
Free Yearly Update On Purchase Of Multi/Corporate License
Companies Served Till Date
